Jazz Pharmaceuticals PLC

JAZZ Healthcare Biotechnology

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 126.0%, free cash flow grew 141.0% and total debt fell 18.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

210.05 4.37 −2.04%
Market cap
$13.9B
P/E
13.8×
Fwd P/E
17.3×
Dividend yield
—
F-score
5/9
Altman Z
1.37
Beneish M
−3.03
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
22.11% 0.68% (8.47%) (8.80%)

+8 more TTM periods

Piotroski F-Score
7 6 5 5
ROA
8.54% 0.25% (3.01%) (3.03%)
ROIC
8.06% (0.34%) (3.72%) (4.24%)
Return on Tangible Assets
48.26% 1.16% (16.77%) (21.41%)
Average Days of Receivables
69.88 68.77 71.05 67.10
Free Cash Flow per Share
22.41 5.07 5.18 6.28
Free Cash Flow
1,416.54 313.74 316.14 380.97
Other line items

Show all line items

Columns are period end dates